Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Celecoxib helps prevent restenosis and appears safe

17.08.2007
Adjunctive use of the COX-2 inhibitor celcoxib after stent implantation in patients with coronary artery disease is safe and can reduce the need for revascularisation of the target lesion, conclude authors of an Article published in this week’s Cardiology Special Issue of The Lancet.

But an accompanying Comment warns that clinical trials suggest long-term use of celecoxib can expose patients to an additional risk of heart attack.

Dr Hyo-Soo Kim, Seoul National University Hospital, Seoul, South Korea and colleagues have published the results of the COREA-TAXUS trial, which aimed to test whether the COX-2 inhibitor celecoxib could prevent the formation of smooth muscle tissue (neointima) within stents, which can lead to narrowing and eventually re-blockage of the lumen of the stent (restenosis).

They studied 274 patients, all of whom were given aspirin (100mg) daily and clopidogrel (75mg daily). Of these, 136 were randomly assigned to receive celecoxib (400mg before the stent implantation, and then 200mg twice daily for 6 months after the procedure). The in-stent lumen diameter of all patients was measured using a coronary angiography six months after stent implantation.

The researchers found that the average reduction on in-stent luminal diameter was 0.49mm in the celecoxib group and 0.75mm in the control group, meaning that celecoxib reduced the luminal reduction by 35%. There was also a decreased need for target-lesion revascularisation in the celecoxib group.

The authors say: “These data suggest that the adjunctive use of celecoxib for 6 months after stent implantation in patients with coronary artery is safe.” They add that unlike with another COX-2 inhibitor rofecoxib, celecoxib does not increase the risk of cardiovascular events. They say: “Administration of celecoxib for 6 months does not seem to increase the risk of adverse cardiac events in the intermediate term when used with dual anti-platelet therapy. We will be interested to see the 2-5 year follow-up results of this cohort.”

In the accompanying Comment, Drs Francesco Pelliccia and Vincenzo Pasceri, Interventional Cardiology Unit, Ospedale San Filippo Neri, Rome, Italy say that the safety of celecoxib needs to be confirmed by studies to assess risk of heart attack and cardiac death, and that gastrointestinal tolerability of celecoxib in combination with aspirin and clopidogrel could also be a drawback.

However the Comment authors conclude: “The study by Koo and colleagues underscores that systemic therapy might still have a role in prevention of restenosis, even in the era of drug-eluting stents.”

Tony Kirby | alfa
Further information:
http://www.thelancet.com/webfiles/images/clusters/thelancet/press_office/celecoxib.pdf

More articles from Health and Medicine:

nachricht Indications of Psychosis Appear in Cortical Folding
26.04.2018 | Universität Basel

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Why we need erasable MRI scans

New technology could allow an MRI contrast agent to 'blink off,' helping doctors diagnose disease

Magnetic resonance imaging, or MRI, is a widely used medical tool for taking pictures of the insides of our body. One way to make MRI scans easier to read is...

Im Focus: BAM@Hannover Messe: innovative 3D printing method for space flight

At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.

Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

World's smallest optical implantable biodevice

26.04.2018 | Power and Electrical Engineering

Molecular evolution: How the building blocks of life may form in space

26.04.2018 | Life Sciences

First Li-Fi-product with technology from Fraunhofer HHI launched in Japan

26.04.2018 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>